Where Will Nvidia Stock Be in 10 Years?
If you had bought $1,000 worth of Nvidia (NASDAQ: NVDA) stock 10 years ago, you would have over $220,000 today — a life-changing return that demonstrates the power of long-term investing. During that time, the company has frequently crashed, only to bounce back stronger than ever.
Past performance doesn’t guarantee future returns, especially for a company already worth $2.93 trillion. But let’s explore what the next decade could have in store for this iconic chipmaker and its shareholders.
A history of boom and bust cycles
Founded in 1993, Nvidia helped pioneer the graphics processing unit (GPU), a computer chip that excels at performing multiple tasks simultaneously. This hardware was a natural fit for the video game industry, where Nvidia quickly became a top supplier for early consoles and gaming computers when 3D rendering was new and exciting.
By the 2010s and onward, GPUs found a new use case in cryptocurrency mining, leading to surging sales and even shortages for many of Nvidia’s advanced consumer-focused hardware. After COVID, the company fell into a major slump as gaming and mining demand nosedived.
However, the launch of Open AI’s ChatGPT in late 2022 gave the company a new lease on life. And now, its data center segment has overshadowed its formerly core businesses. In the fiscal second quarter, data center sales surged 154% year over year to $26.3 billion (88% of sales) on strong demand for enterprise GPUs. The gaming and PC segment only expanded by 16% to $2.9 billion (10% of sales).
How long will the AI boom last?
History tells us that Nvidia is a highly cyclical company, which means its business performance can follow macroeconomic or industry trends outside of management’s control. And while the company has done a good job responding to surging AI hardware demand, it can’t single-handedly keep the industry afloat if demand weakens. This is something long-term investors should watch out for.
While AI chatbots can be fun to play with, they have (so far) fallen short of the transformational megatrend promised. According to some analysts at Goldman Sachs, enterprise companies may never recoup the $1 trillion they are expected to spend on AI-enabling hardware over the next few years because of the technology’s poor monetization potential due to computing costs and competition from free, open-source models.
Nvidia’s management disagrees. CFO Colette Kress claims that cloud providers could earn $5 over the next four years for every $1 spent on Nvidia hardware today. However, these enterprise customers are still on the infrastructure side of the industry. The real challenge will be monetizing consumer-facing AI software, which will need to generate profits to sustain demand for enabling hardware and infrastructure.
Nvidia over the next decade
While it is impossible to predict the future, generative AI hype could eventually fade, just like Nvidia’s other boom cycles in gaming and cryptocurrency. The good news is that GPUs are a very adaptable technology platform. And they are already finding new use cases.
Over the next decade, investors should look for Nvidia to expand into highly synergistic spaces like self-driving cars, augmented reality, and warehouse robotics as the technology improves. The company’s brand loyalty (driven by unique software solutions like CUDA) could help it dominate these new opportunities just like it did with generative AI.
From a valuation perspective, Nvidia’s stock is not expensive at 43 times forward earnings, considering its triple-digit growth rate. However, investors should see this discount as a sign that the market is becoming less confident in Nvidia’s ability to maintain current growth levels. Investors may want to wait until the AI bubble potentially deflates before taking a position in the stock.
Should you invest $1,000 in Nvidia right now?
Before you buy stock in Nvidia, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Nvidia wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Nvidia made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation, you’d have $630,099!*
Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than quadrupled the return of S&P 500 since 2002*.
*Stock Advisor returns as of September 3, 2024
Will Ebiefung has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Nvidia. The Motley Fool has a disclosure policy.
Where Will Nvidia Stock Be in 10 Years? was originally published by The Motley Fool
Trump Brothers' Cryptocurrency Start-Up Rattles Father's Crypto Allies: 'This Is A Huge Mistake'
A cryptocurrency startup spearheaded by Donald Trump‘s sons, Donald Jr. and Eric Trump, has sparked concerns among some of Trump’s most loyal allies within the crypto sector.
What Happened: The Trump siblings have been publicizing their forthcoming cryptocurrency firm, World Liberty Financial, over the past few weeks.
However, according to the report by Politico, the venture has been plagued with a series of setbacks, including hacking incidents involving Trump family members and worries about World Liberty’s intimate connection to a blockchain company that lost $2 million due to security breaches.
“This is a huge mistake,” Nic Carter, a partner at crypto venture capital firm Castle Island Ventures and a Trump supporter, told the outlet.
“It seems like Trump’s inner circle is just cashing in on his recent endorsement of crypto in an unsophisticated manner, and frankly it appears as though they’re squandering a lot of the goodwill that’s been established with the industry so far,” he added.
Earlier this week, accounts belonging to Trump’s daughter-in-law and daughter were compromised and used to advertise a crypto token allegedly from the Trump brothers’ startup.
Also Read: Trump Vs Harris: Majority Of US Crypto Owners Support This Candidate
This prompted the company to warn individuals not to click on any links or buy any tokens shared from their profiles.
According to the outlet, a representative for World Liberty, Zak Folkman, has said that “building a world-class decentralized finance platform with the absolute best of the best in the industry.”
He also said that unauthorized X posts and the fake Telegram channel were reported to the two platforms. Folkman confirmed that Lara, who is Eric Trump’s wife, and Tiffany Trump, Donald Trump’s daughter, are uninvolved in the project.
Furthermore, there are doubts about the team at World Liberty Financial. The Trump brothers’ firm circulating a white paper that outlines a borrowing and lending service akin to Dough Finance, a blockchain app that was hacked for $2 million in July.
The four individuals who established Dough Finance are listed as team members of World Liberty Financial.
Despite these issues, Donald Trump has vowed to make the United States the “crypto capital of the planet” if he wins the presidency again in November, leading to claims that his crypto policymaking could favor his family.
Why It Matters: The Trump family’s entry into the crypto world has been met with skepticism and concern, particularly due to the recent hacking incidents and the connection to a previously compromised blockchain company.
This venture could potentially impact the reputation and acceptance of cryptocurrency in the political sphere, especially if it is perceived as a way for the Trump family to profit from Donald Trump’s potential return to the presidency.
Read Next
Trump’s Crypto Reversal: Ex-President Reportedly Holds More Than $1M In Digital Assets
This content was partially produced with the help of Benzinga Neuro and was reviewed and published by Benzinga editors.
Photo: Shutterstock
Market News and Data brought to you by Benzinga APIs
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
E. Jean Carroll Case: Appeals Court Skeptical of Trump's Bid to Overturn Sexual Abuse Verdict
In a Manhattan courtroom on Friday, Donald Trump came within feet of E. Jean Carroll, one of his most prominent accusers, as they attended oral arguments for his appeal of the $5 million jury verdict from last year that found him liable for sexual abuse and defamation.
A panel of three federal judges from the 2nd Circuit Court of Appeals showed skepticism toward Trump’s effort to overturn the May 2023 verdict, reported Politico.
The verdict had determined he sexually abused Carroll in Bergdorf Goodman’s dressing room in the mid-1990s and later labeled her claim a “hoax.”
Trump did not look at Carroll in court, even as he walked directly in front of her upon entering the room. When Carroll’s lawyer, Roberta Kaplan, stated that Trump had sexually assaulted Carroll, he barely shook his head in response.
The arguments on Friday did not address Carroll’s testimony directly but focused on the admissibility of testimony from another witness, Jessica Leeds, who alleged Trump groped her on a 1979 airplane, and the “Access Hollywood” tape from 2005, in which Trump bragged about grabbing women by their private parts.
Trump’s attorney, D. John Sauer, labeled the case as a “quintessential ‘he said, she said’ case” and accused Carroll of having a “political motive” to tarnish Trump’s reputation.
Sauer contended that Jessica Leeds’ testimony about the alleged 1979 airplane incident should be excluded because there was no federal law against sexual assault on an airplane at that time. However, Kaplan argued that a law prohibiting “simple assault” was in effect then, stating, “It was a crime then to grope someone on a plane. It is a crime today to grope someone on a plane.”
Sauer also argued that the Access Hollywood tape should not be considered a “confession” as claimed by Carroll’s lawyers because it does not refer to any specific incident. Judge Denny Chin responded that it was a “confession about a modus operandi,” to which Sauer replied that “modus operandi itself is inadmissible.”
The panel deciding Trump’s appeal is made up of three judges appointed by Democratic presidents: Chin and Judge Susan Carney by Barack Obama, and Judge Myrna Pérez by Joe Biden.
During the arguments, which lasted just over 20 minutes, Trump remained expressionless. As he left the courtroom, he ignored a reporter’s question about whether he was satisfied with the proceedings.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Now Read:
Market News and Data brought to you by Benzinga APIs
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
SAGE INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Sage Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Case
SAN DIEGO, Sept. 07, 2024 (GLOBE NEWSWIRE) — The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Sage Therapeutics, Inc. SAGE securities between April 12, 2021 and July 23, 2024, both dates inclusive (the “Class Period”), have until October 28, 2024 to seek appointment as lead plaintiff of the Sage Therapeutics class action lawsuit. Captioned Korver v. Sage Therapeutics, Inc., No. 24-cv-06511 (S.D.N.Y.), the Sage Therapeutics class action lawsuit charges Sage Therapeutics as well as certain of Sage Therapeutics’ top executives with violations of the Securities Exchange Act of 1934.
If you suffered substantial losses and wish to serve as lead plaintiff of the Sage Therapeutics class action lawsuit, please provide your information here:
https://www.rgrdlaw.com/cases-sage-therapeutics-inc-class-action-lawsuit-sage.html
You can also contact attorneys J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at info@rgrdlaw.com.
CASE ALLEGATIONS: Sage Therapeutics is a biopharmaceutical company that develops and commercializes brain health medicines. According to the Sage Therapeutics class action lawsuit, Sage Therapeutics is developing, among other things, zuranolone (SAGE-217/BIIB125), a neuroactive steroid for the treatment of postpartum depression (“PPD”) and major depressive disorder (“MDD”), in collaboration with Biogen Inc.; SAGE-718 (dalzanemdor), an oral, oxysterol-based positive allosteric modulator of the N-methyl-D-aspartate receptor for the treatment of, among other things, mild cognitive impairment (“MCI”) due to Parkinson’s Disease (“PD”); and SAGE-324 (BIIB124), an oral investigational drug for the treatment of essential tremor (“ET”), also in collaboration with Biogen.
The Sage Therapeutics class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) zuranolone was less effective in treating MDD than defendants had led investors to believe; (ii) accordingly, the U.S. Food and Drug Administration (“FDA”) was unlikely to approve the zuranolone New Drug Application (“NDA”) for the treatment of MDD in its present form, and zuranolone’s clinical results for MDD, as well as its overall regulatory and commercial prospects, were overstated; (iii) dalzanemdor was less effective in treating MCI due to PD than defendants had led investors to believe; (iv) accordingly, dalzanemdor’s clinical, regulatory, and commercial prospects as a treatment for MCI due to PD were overstated; (v) SAGE-324 was less effective in treating ET than defendants had led investors to believe; and (vi) accordingly, SAGE-324’s clinical, regulatory, and commercial prospects as a treatment for ET were overstated.
The Sage Therapeutics class action lawsuit further alleges that on August 4, 2023, Sage Therapeutics disclosed that the FDA had only approved the zuranolone NDA insofar as it sought zuranolone as a treatment for adults with PPD and had “issued a Complete Response Letter (CRL) for the [NDA] for zuranolone in the treatment of adults with [MDD]” because “the application did not provide substantial evidence of effectiveness to support the approval of zuranolone for the treatment of MDD,” advising that “an additional study or studies will be needed” for that additional indication. On this news, the price of Sage Therapeutics stock fell nearly 54%, according to the complaint.
Then, on April 17, 2024, the Sage Therapeutics class action lawsuit further alleges that Sage Therapeutics disclosed that a Phase 2 study of dalzanemdor as a treatment for MCI due to PD “did not meet its primary endpoint of demonstrating statistically significant difference from baseline in participants treated with once-daily dalzanemdor [SAGE-718] versus placebo on the Wechsler Adult Intelligence Scale Fourth Edition-IV (WAIS-IV) Coding Test score at Day 42,” and that “[b]ased on the data, [Sage Therapeutics] does not plan any further development of dalzanemdor (SAGE-718) in PD.” On this news, the price of Sage Therapeutics stock fell nearly 20%, according to the complaint.
Finally, on July 24, 2024, Sage Therapeutics disclosed that a Phase 2 study of SAGE-324 as a treatment for ET “did not demonstrate a statistically significant dose-response relationship in change from baseline to Day 91 based on the primary endpoint, The Essential Tremor Rating Assessment Scale (TETRAS) Performance Subscale (PS) Item 4 (upper limb) total score, in participants with ET”; that “there were no statistically significant differences demonstrated for any dose of SAGE-324 versus placebo in the change from baseline to Day 91 on the TETRAS PS Item 4 Total Score or the TETRAS Activities of Daily Living (ADL) Composite Score”; and that “[g]iven these results, Sage and Biogen will close the ongoing open label safety study of SAGE-324 in ET and do not plan to conduct further clinical development of SAGE-324 in ET.” According to the Sage Therapeutics class action lawsuit, on this news, the price of Sage Therapeutics stock fell nearly 21%.
THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Sage Therapeutics securities during the Class Period to seek appointment as lead plaintiff in the Sage Therapeutics class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Sage Therapeutics class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Sage Therapeutics class action lawsuit. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Sage Therapeutics class action lawsuit.
ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world’s leading law firms representing investors in securities fraud cases. Our Firm has been #1 in the ISS Securities Class Action Services rankings for six out of the last ten years for securing the most monetary relief for investors. We recovered $6.6 billion for investors in securities-related class action cases – over $2.2 billion more than any other law firm in the last four years. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs’ firms in the world and the Firm’s attorneys have obtained many of the largest securities class action recoveries in history, including the largest securities class action recovery ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information:
https://www.rgrdlaw.com/services-litigation-securities-fraud.html
Attorney advertising.
Past results do not guarantee future outcomes.
Services may be performed by attorneys in any of our offices.
Contact:
Robbins Geller Rudman & Dowd LLP
J.C. Sanchez, Jennifer N. Caringal
655 W. Broadway, Suite 1900, San Diego, CA 92101
800-449-4900
info@rgrdlaw.com
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
$1B In 26 Days: This Marijuana Company Is Capitalizing On Ohio's Cannabis Surge
The launch of Ohio’s recreational cannabis market on August 6 has set the stage for significant growth, with early data showing a 45% sales increase at various marijuana shops in just two weeks. Wholesale performance has also been strong.
“Ohio began non-medical sales on 8/6/24, but full AU rules aren’t out yet, limiting growth. In the first 26 days, total rec/med sales reached $75.6M, implying an annualized run rate of $1.06B, compared to $480M in 2Q24 (just med). We expect Ohio to reach 3-4x its current med base once the full AU program is in place,” Pablo Zuanic, senior analyst at Zuanic & Associates, wrote in a Friday night note.
This positions cannabis company Vext Science Inc. VEXTF as a rising contender among multi-state operators (MSOs).
Get Benzinga’s exclusive analysis and top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter here. If you’re serious about the business, you can’t afford to miss out.
2Q24 Financial Performance
Despite positive trends in Ohio, Vext’s overall sales declined by 8% year-over-year in the second quarter, primarily due to challenges in Arizona where sales, which accounted for 61% of total revenue, fell by 34%, driven by price deflation and increased competition.
Zuanic’s report noted that despite outperforming the state average, Vext’s Arizona stores still faced pressures. On the other hand, Ohio sales grew by 141%, partially boosted by mergers and acquisitions.
“Vext’s profitability suffered due to startup costs in Ohio, with gross margins in both states declining by around 10 percentage points year-over-year,” Zuanic wrote.
Read Also: Ohio’s Sales Surge Might Cast Trouble For Michigan’s Cannabis Market: Here’s Why
Valuation And Future Projections
Zuanic highlighted Vext’s current enterprise value (EV) of $77 million with a market cap of $43 million and $32 million in net debt. On a forward-looking basis, he projects that Vext could achieve a fivefold increase in valuation by late 2025, trading at 1.2x sales and 4.5x EBITDA by 4Q25.
“The company’s high EBITDA torque to Ohio’s recreational market makes it a compelling investment within the MSO group,” added the senior analyst.
With further store expansions planned in Ohio and improvements in Arizona, Vext is expected to generate positive free cash flow (FCF) in the coming quarters, per the report.
Read Next: The King Of Ohio’s Recreational Cannabis Market? Here’s Why Investors Should Follow This Weed Stock
Market News and Data brought to you by Benzinga APIs
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Betting On U.S. Elections? Federal Judge's Decision Greenlights Political Wagers
Prepare for legalized betting on whether Democrats will reclaim the House of Representatives — starting as soon as next week.
On Friday, a federal judge authorized Americans to place bets on congressional election outcomes through a prediction-market startup, paving the way for legalized wagers on U.S. elections, reported the Wall Street Journal.
In a one-page ruling, U.S. District Judge Jia Cobb of the District of Columbia supported the prediction-market startup Kalshi and overturned a 2023 Commodity Futures Trading Commission decision that had prevented Kalshi from offering congressional-control contracts.
According to Kalshi co-founder Luana Lopes Lara in an interview, the company plans to launch its congressional-control contracts for trading next week and swiftly introduce additional political-event contracts, the Journal added.
Last year, Kalshi filed a lawsuit against the CFTC, claiming the regulator had exceeded its authority by blocking the contracts. These contracts would enable investors to bet on whether Republicans or Democrats win control of the House or Senate during election years.
“Election markets are now legal in the United States for the first time in 100 years. Americans will finally be able to trade the election on a U.S.-regulated market,” the startup’s CEO and co-founder, Tarek Mansour, said in a statement.
A CFTC spokesperson stated that the commission is currently reviewing the ruling and had no immediate comment.
The CFTC may appeal the judge’s decision. Judge Cobb, appointed by President Joe Biden, did not provide the reasoning behind her ruling immediately, noting that it would be outlined in a “forthcoming” memorandum.
When the CFTC rejected Kalshi’s contracts last year, it argued that political-event contracts constituted gambling and were, therefore, illegal under federal financial market laws. CFTC Chair Rostin Behnam also expressed concern that approving these contracts could entangle the agency in complex, politically sensitive investigations into election manipulation.
Additionally, opponents of election betting have argued that offering financial incentives for voting could fundamentally distort the electoral process.
Election betting is prohibited in many states, including Nevada, but is permitted in some countries like the U.K., where bookmakers actively accept wagers on U.S. elections.
Kalshi’s supporters argue that its proposed contracts would offer a safer alternative to foreign betting platforms and provide valuable data for political analysis.
The ruling comes as Polymarket, a crypto-based prediction market, has seen hundreds of millions of dollars wagered on the November presidential election. Polymarket has been unavailable to U.S. users since a 2021 settlement with the CFTC, yet it has experienced a surge in trading volumes, particularly on the race between former President Donald Trump and Vice President Kamala Harris.
With this court decision, Kalshi hopes to gain an edge over its offshore competitor by introducing its own election contracts, The Wall Street Journal added.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Read Next:
Market News and Data brought to you by Benzinga APIs
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Will Kamala Harris or Donald Trump Be Better for the Economy? Here's What 1 Top Wall Street Analyst Says
As the U.S. economy goes, so goes the stock market. At least, that’s generally the case. When the economy is strong, corporate earnings tend to rise. And when earnings rise, stocks usually move higher.
With the presidential election just around the corner, many investors are understandably interested in how the policies of the two major candidates might affect the economy. Will Kamala Harris or Donald Trump be better for the economy? Here’s what one top Wall Street analyst says.
The clear winner, according to Goldman Sachs
Goldman Sachs (NYSE: GS) is a financial services giant with operations spanning the globe. It’s a leading investment bank and offers asset and wealth management services. Because of the intersection between politics and its business, the firm recently evaluated the potential impact of Harris’ and Trump’s proposed economic policies.
There’s a clear winner between the two based on how their policies would affect the U.S. economy, in Goldman Sachs’ view. It’s Kamala Harris.
The Wall Street firm projects that under a Harris administration with Democratic control of Congress, jobs would grow by around 10,000 per month higher than if Trump wins with a divided Congress. A Harris win would create 30,000 more jobs per month compared to a sweep where Trump becomes president and the GOP controls both the Senate and the House of Representatives.
Goldman Sachs analysts also predicted that Trump’s economic plans would reduce gross domestic product (GDP) by around 0.5% in the second half of 2025. However, they think this negative impact to GDP would diminish beginning in 2026.
Why the Wall Street firm views Harris’ policies more favorably
Vice President Harris has proposed economic policies including expanded child tax credits, bans on price gouging, tax incentives for first-time homebuyers, and an increase in the corporate tax rate from 21% to 28%. She also recently called for raising the long-term capital gains tax rate to 28% for Americans who earn $1 million or more and giving up to $50,000 in tax deductions for new small businesses.
Former President Trump wants to reduce corporate tax rates to 15%. He proposes tariffs of at least 10% on all imports with tariffs of 60% on imports from China. Trump also plans to reduce government regulations to help businesses. His idea of a massive deportation of illegal immigrants could have an economic impact as well.
Goldman Sachs likes Harris’ proposed spending initiatives and tax credits for the middle class. The firm projects these plans would “slightly more than offset investment due to higher corporate tax rates.” The result, in Goldman Sachs’ view, is that a Harris administration with a Democratic Congress would boost GDP growth a little in 2025 and 2026.
The Wall Street firm has a negative take on Trump’s economic proposals, however. Goldman Sachs analysts wrote to investors earlier this week, “We estimate that if Trump wins in a sweep or with [divided] government, the hit to growth from tariffs and tighter immigration policy would outweigh the positive fiscal impulse.”
What’s the potential impact on investors?
Not everyone agrees with Goldman Sachs’ outlook. The Trump campaign responded to an inquiry from Bloomberg: “[T]hese Wall Street elites would be wise to review the record and acknowledge the shortcomings of their past work if they’d like their new forecast to be seen as credible.”
Unsurprisingly, the Harris campaign liked Goldman Sachs’ analysis. It released a statement saying, “Vice President Harris has a positive vision to strengthen the economy by building up the middle class, cutting taxes and lowering costs for working families and small businesses, and creating opportunities for all Americans to get ahead.”
What’s the potential impact on investors if Goldman Sachs’ take is right? The easy answer is that it depends on who wins in November. However, the stock market has risen in the past during both Democratic and Republican administrations. For long-term investors, the occupant of the Oval Office over the next four years won’t matter nearly as much as the quality of the stocks they buy and how long they own those stocks.
Should you invest $1,000 in Goldman Sachs Group right now?
Before you buy stock in Goldman Sachs Group, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Goldman Sachs Group wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Nvidia made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation, you’d have $656,938!*
Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than quadrupled the return of S&P 500 since 2002*.
*Stock Advisor returns as of September 3, 2024
Keith Speights has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Goldman Sachs Group. The Motley Fool has a disclosure policy.
Will Kamala Harris or Donald Trump Be Better for the Economy? Here’s What 1 Top Wall Street Analyst Says was originally published by The Motley Fool
MDB DEADLINE REMINDER: MongoDB, Inc. Investors who Lost Money are Reminded to Contact BFA Law before Upcoming Securities Litigation Deadline (Nasdaq:MDB)
NEW YORK, Sept. 07, 2024 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces a lawsuit has been filed against MongoDB, Inc. (“MongoDB” or the “Company”) MDB and certain of the Company’s senior executives.
If you suffered losses on your MongoDB investment, you are encouraged to submit your information at https://www.bfalaw.com/cases-investigations/mongodb-inc.
Investors have until September 9, 2024 to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in MongoDB securities. The case is pending in the U.S. District Court for the Southern District of New York and is captioned John Baxter v. MongoDB, Inc., et al., No. 1:24-cv-05191.
What is the Lawsuit About?
The complaint alleges that the Company misrepresented the purported benefits stemming from the restructuring of its sales force. This includes how the restructuring helped reduce friction in acquiring new customers and increased new workload acquisition among existing customers.
These statements were allegedly materially false and misleading. In truth, MongoDB’s sales force restructuring resulted in a near total loss of upfront customer commitments, a significant reduction in actionable information gathered by the sales force, and hindered enrollment and revenue growth.
On March 7, 2024, the Company allegedly announced that due to the sales restructuring, it experienced an annual decrease of approximately $40 million in multiyear license revenue, anticipated near zero revenue from unused Atlas commitments (one of its core offerings) in fiscal year 2025, and provided a disappointing revenue growth forecast that trailed that of the prior year. This news caused the price of MongoDB stock to decline $28.59 per share, or about 7%, from $412.01 per share on March 7, 2024, to $383.42 per share on March 8, 2024.
Then, on May 30, 2024, the Company again announced significantly reduced growth expectations, this time cutting fiscal year 2025 growth projections further, again attributing the losses to the sales force restructuring. On this news, the price of MongoDB stock declined $73.94 per share, or nearly 24%, from $310.00 per share on May 30, 2024, to $236.06 per share on May 31, 2024.
Click here if you suffered losses: https://www.bfalaw.com/cases-investigations/mongodb-inc.
What Can You Do?
If you invested in MongoDB, Inc. you have rights and are encouraged to submit your information to speak with an attorney.
All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The Firm will seek court approval for any potential fees and expenses. Submit your information:
https://www.bfalaw.com/cases-investigations/mongodb-inc
Or contact us at:
Ross Shikowitz
ross@bfalaw.com
212-789-3619
Why Bleichmar Fonti & Auld LLP?
Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been named Titans of the Plaintiffs’ Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors (pending court approval), as well as $420 million from Teva Pharmaceutical Ind. Ltd.
For more information about BFA and its attorneys, please visit https://www.bfalaw.com.
https://www.bfalaw.com/cases-investigations/mongodb-inc
Attorney advertising. Past results do not guarantee future outcomes.
Market News and Data brought to you by Benzinga APIs
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
MEDIA ADVISORY – FEDERAL GOVERNMENT TO MAKE HOUSING ANNOUNCEMENT IN DARTMOUTH
DARTMOUTH, NS, Sept. 6, 2024 /CNW/ – Media are invited to join Darren Fisher, Member of Parliament for Dartmouth–Cole Harbour on behalf of the Honourable Sean Fraser, Minister of Housing, Infrastructure and Communities, the Honourable Timothy Halman, provincial Minister of Environment and Climate Change and Member of Legislative Assembly for Dartmouth East on behalf of the Honourable John Lohr, Minister of Municipal Affairs and Housing and Miia Soukonau, Executive Director, YWCA Halifax.
|
Date: |
September 8, 2024 |
|
Time: |
12:00 pm AT |
|
Location: |
29 Kassi Lane |
|
Dartmouth, NS B2Y 0G9 |
SOURCE Government of Canada
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/September2024/06/c7096.html
Market News and Data brought to you by Benzinga APIs
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Major Exercise Alert: LISA WARDELL Exercises Options Worth $2.17M At Adtalem Glb Education
On September 5, it was revealed in an SEC filing that LISA WARDELL, Director at Adtalem Glb Education ATGE executed a significant exercise of company stock options.
What Happened: A Form 4 filing with the U.S. Securities and Exchange Commission on Thursday revealed that WARDELL, Director at Adtalem Glb Education in the Consumer Discretionary sector, exercised stock options for 54,207 shares of ATGE stock. The exercise price of the options was $32.03 per share.
The latest update on Friday morning shows Adtalem Glb Education shares down by 0.0%, trading at $72.05. At this price, WARDELL’s 54,207 shares are worth $2,169,364.
All You Need to Know About Adtalem Glb Education
Adtalem Global Education Inc is an American for-profit educational company that operates various university and educational programs. The company has three segments namely Chamberlain; Walden; and Medical and Veterinary. It derives maximum revenue from Chamberlain segment.
Understanding the Numbers: Adtalem Glb Education’s Finances
Revenue Growth: Adtalem Glb Education displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 12.41%. This indicates a notable increase in the company’s top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Consumer Discretionary sector.
Interpreting Earnings Metrics:
-
Gross Margin: The company sets a benchmark with a high gross margin of 55.47%, reflecting superior cost management and profitability compared to its peers.
-
Earnings per Share (EPS): Adtalem Glb Education’s EPS is notably higher than the industry average. The company achieved a positive bottom-line trend with a current EPS of 1.29.
Debt Management: Adtalem Glb Education’s debt-to-equity ratio is notably higher than the industry average. With a ratio of 0.62, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
Analyzing Market Valuation:
-
Price to Earnings (P/E) Ratio: Adtalem Glb Education’s P/E ratio of 21.07 is below the industry average, suggesting the stock may be undervalued.
-
Price to Sales (P/S) Ratio: The P/S ratio of 1.83 is lower than the industry average, implying a discounted valuation for Adtalem Glb Education’s stock in relation to sales performance.
-
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation & Amortization): The company’s EV/EBITDA ratio 10.25 is below the industry average, indicating that it may be relatively undervalued compared to peers.
Market Capitalization Perspectives: The company’s market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.
Why Insider Transactions Are Key in Investment Decisions
While insider transactions provide valuable information, they should be part of a broader analysis in making investment decisions.
From a legal standpoint, the term “insider” pertains to any officer, director, or beneficial owner holding more than ten percent of a company’s equity securities as outlined in Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and significant hedge funds. These insiders are mandated to inform the public of their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
A company insider’s new purchase is a indicator of their positive anticipation for a rise in the stock.
While insider sells may not necessarily reflect a bearish view and can be motivated by various factors.
Deciphering Transaction Codes in Insider Filings
Surveying the realm of stock transactions, investors often give prominence to those unfolding in the open market, systematically detailed in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C denotes the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
Check Out The Full List Of Adtalem Glb Education’s Insider Trades.
This article was generated by Benzinga’s automated content engine and reviewed by an editor.
Market News and Data brought to you by Benzinga APIs
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.